BioSpace News Archive

HEXO Corp. (TSX: HEXO;NYSE: HEXO) (“HEXO” or the “Company”) today reported its financial results for the third quarter fiscal 2020 ended April 30, 2020

egeneron utilized ‘rapid response’ VelociSuite® technologies to identify pairs of potent and complementary antibodies that could be combined into antibody ‘cocktails’ for COVID-19

Celltrion (KRX:068270) announced today that it has signed an agreement to acquire product assets for the Asia Pacific region from Takeda Pharmaceuticals International AG (“Takeda”) in an effort to strengthen its R&D capabilities in the Global Small Molecule Drug sector.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a company overview at the Raymond James 2020 Human Health Innovation Conference

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week. The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the curr

Regeneron Pharmaceuticals, Inc. announced initiation of the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19.

Deciphera Pharmaceuticals, Inc. announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:40 PM ET.

Growth & Emerging Markets Business Unit increasing focus on innovative medicines for complex and rare diseases

Exploratory analysis from FARXIGA DAPA-HF Phase III trial will provide insights on the onset of type 2 diabetes in heart failure patients

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: A fireside chat at the JMP Securities Hematology & Oncology Forum on Thursday, June 18, 2020 at 4:20 p.m. ET / 1:20 p.m. PT; and A fireside chat at the